Neximmune Inc
NEXI
Get informed when a big investor buys or sells
+ FollowMarket Cap$139
Close$
$2.99
2985800% upside
Current Fair Value
2985800% upsideUndervalued by 2985800% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $139.00 |
|---|---|
| Enterprise Value | $-2,424,111,861.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-30.82 |
| Beta | 3.93 |
| Outstanding Shares | 1,380,395 |
Return
| Return on Equity | -336.76% |
|---|---|
| Return on Assets | -40.01% |
| Return on Invested Capital | -313.59% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -1143.15 |
| Enterprise Value to EBIT | 0.69 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-13.25
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-16.83
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Neximmune Inc
44 employeesNexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells t...